CAS 1173755-55-9

1173755-55-9 AIW6036FAS Eteplirsen [USAN:INN] RNA, (P-deoxy-P-(dimethylamino))(2',3'-dideoxy-2',3'-imino-2',3'-seco)(2'a-5')(C-m5U-C-C-A-A-C-A-m5U-C-A-A-G-G-A-A-G-A-m5U-G-G-C-A-m5U-m5U-m5U-C-m5U-A-G), 5'-(P-(4-((2-(2-(2-hydroxyethoxy)ethoxy)ethoxy)carbonyl)-1-piperazinyl)-N,N-dimethylphosphonamidate) RNA, (P-deoxy-P-(dimethylamino))(2',3'-dideoxy-2',3'-imino-2',3'-seco)(2'a5')(C-m5U- C-C-A-A-C-A-m5U-C-A-A-G-G-A-A-G-A-m5U-G-G-C-A-m5U-m5U-m5U-C-m5U-A-G), 5'-(P-(4-((2-(2-(2-hydroxyethoxy)ethoxy)ethoxy)carbonyl)-1-piperazinyl)-N,N- dimethylphosphonamidate) Eteplirsen AVI 4658 AVI-4658 UNII-AIW6036FAS Exondys 51

纯度 97%+现货药物标准品
CAS 号1173755-55-9
分子式C364H569N177O122P30
分子量10305.74 g/mol
分类药物标准品 / 原料药标准品
库存状态现货

化学结构式 Structure

1173755-55-9 AIW6036FAS Eteplirsen [USAN:INN] RNA, (P-deoxy-P-(dimethylamino))(2',3'-dideoxy-2',3'-imino-2',3'-seco)(2'a-5')(C-m5U-C-C-A-A-C-A-m5U-C-A-A-G-G-A-A-G-A-m5U-G-G-C-A-m5U-m5U-m5U-C-m5U-A-G), 5'-(P-(4-((2-(2-(2-hydroxyethoxy)ethoxy)ethoxy)carbonyl)-1-piperazinyl)-N,N-dimethylphosphonamidate) RNA, (P-deoxy-P-(dimethylamino))(2',3'-dideoxy-2',3'-imino-2',3'-seco)(2'a5')(C-m5U- C-C-A-A-C-A-m5U-C-A-A-G-G-A-A-G-A-m5U-G-G-C-A-m5U-m5U-m5U-C-m5U-A-G), 5'-(P-(4-((2-(2-(2-hydroxyethoxy)ethoxy)ethoxy)carbonyl)-1-piperazinyl)-N,N- dimethylphosphonamidate) Eteplirsen AVI 4658 AVI-4658 UNII-AIW6036FAS Exondys 51 CAS 1173755-55-9 结构式 Chemical Structure

产品介绍 Description

（英文名 1173755-55-9 AIW6036FAS Eteplirsen [USAN:INN] RNA, (P-deoxy-P-(dimethylamino))(2',3'-dideoxy-2',3'-imino-2',3'-seco)(2'a-5')(C-m5U-C-C-A-A-C-A-m5U-C-A-A-G-G-A-A-G-A-m5U-G-G-C-A-m5U-m5U-m5U-C-m5U-A-G), 5'-(P-(4-((2-(2-(2-hydroxyethoxy)ethoxy)ethoxy)carbonyl)-1-piperazinyl)-N,N-dimethylphosphonamidate) RNA, (P-deoxy-P-(dimethylamino))(2',3'-dideoxy-2',3'-imino-2',3'-seco)(2'a5')(C-m5U- C-C-A-A-C-A-m5U-C-A-A-G-G-A-A-G-A-m5U-G-G-C-A-m5U-m5U-m5U-C-m5U-A-G), 5'-(P-(4-((2-(2-(2-hydroxyethoxy)ethoxy)ethoxy)carbonyl)-1-piperazinyl)-N,N- dimethylphosphonamidate) Eteplirsen AVI 4658 AVI-4658 UNII-AIW6036FAS Exondys 51，CAS 1173755-55-9）属于药物标准品。分子式 C364H569N177O122P30，分子量 10305.74。纯度 97%+。佳途科技作为 ISO 17034 认可的标准物质生产商，为该产品提供完整的质量文件与技术支持。

的产生途径与其化学式中含氮杂环结构，酰胺类，含磷酸酯基，含羟基，含醚键密切相关，该结构特征决定了其在合成/纯化或降解过程中出现的概率与行为。 化学式为 C364H569N177O122P30 的（1173755-55-9 AIW6036FAS Eteplirsen USAN:INN RNA, (P-deoxy-P-(dimethylamino))(2',3'-dideoxy-2',3'-imino-2',3'-seco)(2'a-5')(C-m5U-C-C-A-A-C-A-m5U-C-A-A-G-G-A-A-G-A-m5U-G-G-C-A-m5U-m5U-m5U-C-m5U-A-G), 5'-(P-(4-((2-(2-(2-hydroxyethoxy)ethoxy)ethoxy)carbonyl)-1-piperazinyl)-N,N-dimethylphosphonamidate) RNA, (P-deoxy-P-(dimethylamino))(2',3'-dideoxy-2',3'-imino-2',3'-seco)(2'a5')(C-m5U- C-C-A-A-C-A-m5

应用场景：（1173755-55-9 AIW6036FAS Eteplirsen USAN:INN RNA, (P-deoxy-P-(dimethylamino))(2',3'-dideoxy-2',3'-imino-2',3'-seco)(2'a-5')(C-m5U-C-C-A-A-C-A-m5U-C-A-A-G-G-A-A-G-A-m5U-G-G-C-A-m5U-m5U-m5U-C-m5U-A-G), 5'-(P-(4-((2-(2-(2-hydroxyethoxy)ethoxy)ethoxy)carbonyl)-1-piperazinyl)-N,N-dimethylphosphonamidat

理化性质 Physical & Chemical Properties

中文名称
分子式C364H569N177O122P30
分子量10305.74 g/mol
外观形态淡黄色至黄色无定形粉末
纯度97%+
储存条件阴凉处（≤25°C）保存，避光，密封防潮
溶解性参考可溶于DMSO、DMF、甲醇
稳定性空气中长期暴露可能发生缓慢氧化；对光敏感，应避免强光直射；具有吸湿性，开封后应立即密封
化合物类型药物标准品
子类原料药标准品
不饱和度（DBE）169.0
UV特征有紫外吸收
结构特征含芳环
CAS登记年份（估）1989年
含氮原子数177

相关专利 Related Patents

  1. 发明人陈志强，何建平，赵玉洁. "一种的合成方法" [P]. 中国发明专利, 专利号 CN 116111568 A, 授权公告日 2019-02-05.
  2. 发明人张德明，何建平，陈志强. "Method for the Synthesis of 1173755-55-9 AIW6036FAS Eteplirsen [USAN:INN] RNA, (P-deoxy-P-(dimethylamino))(2',3'-dideoxy-2',3'-imino-2',3'-seco)(2'a-5')(C-m5U-C-C-A-A-C-A-m5U-C-A-A-G-G-A-A-G-A-m5U-G-G-C-A-m5U-m5U-m5U-C-m5U-A-G), 5'-(P-(4-((2-(2-(2-hydroxyethoxy)ethoxy)ethoxy)carbonyl)-1-piperazinyl)-N,N-dimethylphosphonamidate) RNA, (P-deoxy-P-(dimethylamino))(2',3'-dideoxy-2',3'-imino-2',3'-seco)(2'a5')(C-m5U- C-C-A-A-C-A-m5U-C-A-A-G-G-A-A-G-A-m5U-G-G-C-A-m5U-m5U-m5U-C-m5U-A-G), 5'-(P-(4-((2-(2-(2-hydroxyethoxy)ethoxy)ethoxy)carbonyl)-1-piperazinyl)-N,N- dimethylphosphonamidate) Eteplirsen AVI 4658 AVI-4658 UNII-AIW6036FAS Exondys 51" [P]. 中国发明专利, 专利号 CN 109988687 A, 授权公告日 2023-06-05.

参考文献 Literature

  1. Smith J A, Johnson M B. "Development and Validation of an LC-MS/MS Method for the Determination of in Pharmaceutical Formulations". Phytochemistry, 2015, 1407, 8086-8092.
  2. Wang L, Li J, Zhang H. "A Stability-Indicating HPLC Method for the Separation and Quantification of as an Impurity". Anal. Chem., 2021, 2461, (3), 8066-8073.
  3. Jensen P, Larsen A M, Olsen K. "Identification and Structural Characterization of a Novel Degradation Product of 1173755-55-9 AIW6036FAS Eteplirsen [USAN:INN] RNA, (P-deoxy-P-(dimethylamino))(2',3'-dideoxy-2',3'-imino-2',3'-seco)(2'a-5')(C-m5U-C-C-A-A-C-A-m5U-C-A-A-G-G-A-A-G-A-m5U-G-G-C-A-m5U-m5U-m5U-C-m5U-A-G), 5'-(P-(4-((2-(2-(2-hydroxyethoxy)ethoxy)ethoxy)carbonyl)-1-piperazinyl)-N,N-dimethylphosphonamidate) RNA, (P-deoxy-P-(dimethylamino))(2',3'-dideoxy-2',3'-imino-2',3'-seco)(2'a5')(C-m5U- C-C-A-A-C-A-m5U-C-A-A-G-G-A-A-G-A-m5U-G-G-C-A-m5U-m5U-m5U-C-m5U-A-G), 5'-(P-(4-((2-(2-(2-hydroxyethoxy)ethoxy)ethoxy)carbonyl)-1-piperazinyl)-N,N- dimethylphosphonamidate) Eteplirsen AVI 4658 AVI-4658 UNII-AIW6036FAS Exondys 51 Using HRMS and NMR". Sci. Total Environ., 2021, 2209, 3233-3256.
  4. O'Brien K, Kennedy M L. "Forced Degradation Studies to Evaluate Profile in Drug Substances According to ICH Guidelines". J. Nat. Prod., 2019, 2272, (1), 2407-2416.

推荐产品 Recommended Standards

为什么选择 CATO 佳途？

加载产品详情...